*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
• Has over 32 years of experience in pharmacology research and pharmaceutical industry, particularly in oncology, led or supported multiple NDA programs for innovative drugs, most notably Loncastuximab tesirine, a CD-19 ADC for lymphoma, Abivertinib, an EGFR inhibitor for lung cancer, Erdafitinib, an FGFR inhibitor for urothelial cancer, and Dasatinib, a BCR-ABL inhibitor for leukemia
• Received his doctor degree from the University of North Carolina at Chapel Hill
• Served as a senior director at the department of translational medicine and clinical pharmacology in Daiichi Sankyo; served as a director of oncology R&D and a senior leadership team member of experimental medicine and early development at Johnson & Johnson
• Held key leadership positions in certain famous pharmaceutical enterprises including Roche, Bristol-Myers Squibb, etc., with a wealth of experience in translational medicine, clinical development and executive management
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
